353 related articles for article (PubMed ID: 25216271)
1. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
6. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Yuan JQ; Mao C; Wong SY; Yang ZY; Fu XH; Dai XY; Tang JL
Medicine (Baltimore); 2015 Jul; 94(27):e974. PubMed ID: 26166130
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.
Fan Z; Shi H; Zhang J; Wang H; Wang J
Front Pharmacol; 2022; 13():763184. PubMed ID: 35330833
[No Abstract] [Full Text] [Related]
13. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
[TBL] [Abstract][Full Text] [Related]
14. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of an α
Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
[TBL] [Abstract][Full Text] [Related]
19. To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis.
Ma C; Zhang J; Cai Z; Li H
Medicine (Baltimore); 2020 Jan; 99(3):e18712. PubMed ID: 32011446
[TBL] [Abstract][Full Text] [Related]
20. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
